These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1044 related items for PubMed ID: 21472434

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 Jan; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

  • 7. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 8. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [Abstract] [Full Text] [Related]

  • 9. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 10. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [Abstract] [Full Text] [Related]

  • 11. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
    Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C.
    J Clin Oncol; 2012 Jun 01; 30(16):1996-2004. PubMed ID: 22508827
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.
    Breast Cancer Res Treat; 2008 Oct 01; 111(3):411-7. PubMed ID: 17968656
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 01; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 15. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.
    Breast Cancer Res Treat; 2012 Apr 01; 132(3):793-805. PubMed ID: 21562709
    [Abstract] [Full Text] [Related]

  • 16. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 Apr 01; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 17. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM, Lowe KA, Atwood M, Beatty JD.
    Breast J; 2010 Aug 01; 16(4):362-8. PubMed ID: 20443786
    [Abstract] [Full Text] [Related]

  • 19. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):387-91. PubMed ID: 20824324
    [Abstract] [Full Text] [Related]

  • 20. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.
    Magy Onkol; 2009 Dec 01; 53(4):335-43. PubMed ID: 20071305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.